EP3261439 - METHODS AND MATERIALS FOR TREATING HUMAN IMMUNODEFICIENCY VIRUS INFECTIONS [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 15.04.2021 Database last updated on 24.08.2024 | |
Former | Request for examination was made Status updated on 01.12.2017 | ||
Former | The international publication has been made Status updated on 25.09.2017 | Most recent event Tooltip | 22.06.2024 | New entry: Reply to examination report | Applicant(s) | For all designated states Mayo Foundation For Medical Education And Research Minnesota BioBusiness Center - 4th Floor 200 First Street SW Rochester, Minnesota 55905 / US | [2018/01] | Inventor(s) | 01 /
BADLEY, Andrew D. 706 4th Street S.W. Rochester, Minnesota 55902 / US | [2018/01] | Representative(s) | Fish & Richardson P.C. Highlight Business Towers Mies-van-der-Rohe-Straße 8 80807 München / DE | [N/P] |
Former [2018/01] | Kunz, Herbert Fish & Richardson P.C. Highlight Business Towers Mies-van-der-Rohe-Straße 8 80807 München / DE | Application number, filing date | 16756096.0 | 19.02.2016 | [2018/01] | WO2016US18776 | Priority number, date | US201562119318P | 23.02.2015 Original published format: US 201562119318 P | [2018/01] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2016137844 | Date: | 01.09.2016 | Language: | EN | [2016/35] | Type: | A1 Application with search report | No.: | EP3261439 | Date: | 03.01.2018 | Language: | EN | The application published by WIPO in one of the EPO official languages on 01.09.2016 takes the place of the publication of the European patent application. | [2018/01] | Search report(s) | International search report - published on: | US | 01.09.2016 | (Supplementary) European search report - dispatched on: | EP | 11.12.2018 | Classification | IPC: | A61K31/69, A01N37/18, A61K38/55, A61P31/18, A61K38/05, A61K45/06, A61K38/20, A61K31/4402, A61K31/505, A61K31/513, A61K31/5365, A61K31/635, A61K31/675 | [2023/13] | CPC: |
A61K31/69 (EP,US);
A61K31/4402 (EP,US);
A61K31/505 (EP,US);
A61K31/513 (EP,US);
A61K31/5365 (EP,US);
A61K31/635 (EP,US);
A61K31/675 (EP,US);
A61K38/05 (EP,US);
A61K38/2013 (EP,US);
A61K38/2086 (EP,US);
A61K39/21 (US);
A61K45/06 (EP,US);
A61P31/18 (EP)
(-)
| C-Set: |
A61K31/4402, A61K2300/00 (EP,US);
A61K31/505, A61K2300/00 (US,EP);
A61K31/513, A61K2300/00 (US,EP);
A61K31/635, A61K2300/00 (US,EP);
A61K31/675, A61K2300/00 (US,EP);
A61K31/69, A61K2300/00 (EP,US);
A61K38/05, A61K2300/00 (EP,US);
A61K38/2013, A61K2300/00 (EP,US); |
Former IPC [2019/02] | A61K31/69, A01N37/18, A61K38/55, A61P31/18 | ||
Former IPC [2018/01] | A01N37/18, A61K38/55, A61P31/18 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2018/01] | Title | German: | VERFAHREN UND MATERIALIEN ZUR BEHANDLUNG MENSCHLICHER IMMUNSCHWÄCHEVIRUSINFEKTIONEN | [2018/01] | English: | METHODS AND MATERIALS FOR TREATING HUMAN IMMUNODEFICIENCY VIRUS INFECTIONS | [2018/01] | French: | MÉTHODES ET MATIÈRES POUR TRAITER DES INFECTIONS AU VIRUS DE L'IMMUNODÉFICIENCE HUMAINE | [2018/01] | Entry into regional phase | 25.09.2017 | National basic fee paid | 25.09.2017 | Search fee paid | 25.09.2017 | Designation fee(s) paid | 25.09.2017 | Examination fee paid | Examination procedure | 25.09.2017 | Examination requested [2018/01] | 25.09.2017 | Date on which the examining division has become responsible | 15.07.2019 | Amendment by applicant (claims and/or description) | 14.04.2021 | Despatch of a communication from the examining division (Time limit: M04) | 05.08.2021 | Reply to a communication from the examining division | 13.09.2022 | Despatch of a communication from the examining division (Time limit: M06) | 26.01.2023 | Reply to a communication from the examining division | 04.04.2023 | Despatch of a communication from the examining division (Time limit: M04) | 14.08.2023 | Reply to a communication from the examining division | 22.02.2024 | Despatch of a communication from the examining division (Time limit: M04) | 21.06.2024 | Reply to a communication from the examining division | Fees paid | Renewal fee | 27.02.2018 | Renewal fee patent year 03 | 27.02.2019 | Renewal fee patent year 04 | 27.02.2020 | Renewal fee patent year 05 | 25.02.2021 | Renewal fee patent year 06 | 25.02.2022 | Renewal fee patent year 07 | 27.02.2023 | Renewal fee patent year 08 | 29.01.2024 | Renewal fee patent year 09 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [X]WO2006017346 (US GOV SEC TECH TRANSFER [US], et al) [X] 1,2,5,7 * the whole document ** page 22, line 18 *; | [X]WO2011089166 (VIROLOGIK GMBH [DE], et al) [X] 1-3,5-8,10,11,13,14 * the whole document * * page 9, lines 11-22 * * page 23, line 24 - page 24, line 28 * * page 54, line 8 - page 58, line 20 * * page 60, lines 13-26 * * page 64, lines 25-29 * * example 2 * * example 2.2.2 * * example 2.2.3 *; | [X] - YU L ET AL, "Proteasome inhibitors block HIV-1 replication by affecting both cellular and viral targets", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ELSEVIER, AMSTERDAM, NL, vol. 385, no. 1, doi:10.1016/J.BBRC.2009.04.156, ISSN 0006-291X, (20090717), pages 100 - 105, (20090506), XP026337672 [X] 1-3,5,11 * the whole document * * page 102, column 2, paragraph 2 - page 105, column 1, paragraph 2 * DOI: http://dx.doi.org/10.1016/j.bbrc.2009.04.156 | International search | [Y]WO0033654 (UNIV MARYLAND BIOTECH INST [US]) [Y] 11, 13 * page 5 In 11-12, page 9 In 3-6, page 71 In 20 - page 72 In 2. *; | [Y]US2003232738 (FINKEL TERRI H [US], et al) [Y] 11, 12 * para [0010], [0022], [0079] *; | [XY]WO2006017346 (US GOV SEC TECH TRANSFER [US], et al) [X] 1-3, 9-10 * page 8 In 15-16, In 18-20, page 9, In 4-7, page 18 In 27 - page 19 In 2, page 22 In 16-18, page 23 In 1-6, page 44 In 6-8, page 52 In 12-28 * [Y] 4-8, 11-14; | [Y]WO2011089167 (VIROLOGIK GMBH [DE], et al) [Y] 5-8 * page 20 In 5-6, page 21 In 21-24, page35 In13-15, page 35 In 20 - page 36 In 12, page36 In 25-27, page 40 In 8-9. *; | [Y]US2014309289 (ANDERSON JOSEPH [US], et al) [Y] 11, 14* para [0005], [0165] *; | [Y] - MOREAU, "Oral therapy for multiple myeloma: ixazomib arriving soon.", Blood, (20140814), vol. 124, no. 7, pages 986 - 987, XP055485036 [Y] 4 * . page 986 col 3 para 3. * | by applicant | WO2006017346 | WO2011089166 | - HUTTER et al., N. Engl. J. Med., (20090000), vol. 360, pages 692 - 698 | - YU et al., Biochemical and Biophysical Research Communications, (20090717), vol. 385, no. 1, pages 100 - 105 | - BULLEN et al., Nature Medicine, (20140000), vol. 20, pages 425 - 429 | - WARRINER et al., Infect. Dis. Clin. North Am., (20140000), vol. 28, no. 3, pages 457 - 76 | - SALEH et al., Blood, (20070000), vol. 110, pages 4161 - 4164 |